Blog Exposure - FDA Approves Aclaris Therapeutics' ESKATA Topical Solution for Treatment of Common Skin Growths

Stock Monitor: Arrowhead Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 18, 2017 / Active-Investors issued a free report on Aclaris Therapeutics, Inc. (NASDAQ: ACRS), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=ACRS as the Company's latest news hit the wire. On December 15, 2017, the Company announced that the US Food and Drug Administration (FDA) has given approval for ESKATA™ (hydrogen peroxide) topical solution for the treatment of raised seborrheic keratoses (SKs). The key feature of the treatment is that it is completely non-invasive and the first of its kind for treating SKs. Sign up now for our free research reports at:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), which also belongs to the Healthcare sector as the Company Aclaris Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ARWR

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Aclaris Therapeutics most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:

www.active-investors.com/registration-sg/?symbol=ACRS

SKs are common skin growths that are non-cancerous but aesthetically unappealing and usually found in areas like the face and neck. As per an estimate, nearly 83 million American adults are afflicted by this skin condition and typically increases in size as a person ages. The condition is more widespread than the three most common skin conditions - acne, psoriasis, and rosacea put together.

About ESKATA™?

Aclaris' ESKATA™ is a proprietary, non-invasive high-concentration (40%) hydrogen peroxide-based topical solution. It is designed in such a manner that a healthcare provider can easily treat a patient with an in-office application using a pen-like applicator directly on the raised SKs. The treatment is non-invasive has a low risk of scarring. The treatment is recommended only with the consultation of a healthcare provider with expertise in diagnosing skin conditions and is not suitable for use at home

Aclaris' ESKATA™ received approval from FDA after the Company completed two pivotal Phase-3 clinical trials which confirmed the safety and efficacy of ESKATA™ for the treatment of raised SKs. The patients at the clinical trials were given two applications of the treatment, once at the start of the trial and the second application in the third week. The data from these clinical trials indicated that patients treated with ESKATA™ were more likely to have all four treated SKs completely cleared after two treatments compared to those patients who received placebo treatment. The treatment was mostly tolerable for patients treated with ESKATA™. There were some incidences of side effects which included symptoms like itching, stinging, crusting, swelling, redness, and scaling at the site of application.

According to a consumer survey conducted by the American Society for Dermatologic Surgery (ASDS), there is a need for the effective treatment of SKs. Aclaris' ESKATA™ has the distinction of being the first topical treatment option available with physicians to satisfy this unmet patient need. The Company plans to launch the product commercially as a self-pay aesthetic treatment in Q2 2018. The Company has also been planning to commercially launch ESKATA™ in the European markets and has applied for a Marketing Authorization Application (MAA) for ESKATA™ with the European Union.

Management Comments

Commenting on the receipt of FDA's approval for ESKATA™, Dr. Neal Walker, President and CEO of Aclaris., said:

"This achievement delivers on Aclaris' commitment to bringing innovative therapies to market that address significant unmet needs in dermatology. For the first time, with the approval of ESKATA™, patients will have access to an FDA-approved topical, non-invasive treatment for raised SKs."

Stuart D. Shanler, M.D., Chief Scientific Officer of Aclaris, added:

"We are proud to offer ESKATA™ to dermatologists and their patients as a treatment that can clear raised SKs without cutting, burning, or freezing the skin. As a clinician, I saw first-hand that patients preferred non-invasive treatments."

Anne M. Chapas, M.D., FAAD, Founder and Medical Director of Union Square Dermatology, Clinical Instructor of Dermatology, Mount Sinai Medical Center, New York and a consultant for Aclaris. Stated:

"With the approval of ESKATA™, I am pleased to be able to offer my patients a topical treatment option that is well tolerated and can clear raised SKs with a low risk of scarring."

About Aclaris Therapeutics, Inc.

Malvern, Pennsylvania-based Aclaris was founded in 2012 and is a dermatologist-led biopharmaceutical company. It committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology. The Company's focus area is on market segments with no FDA-approved medications or where treatment gaps exist. Aclaris is forging ahead with a diversified aesthetic and medical dermatology and immunodermatology portfolio to treat skin and hair conditions.

Stock Performance Snapshot

December 15, 2017 - At Friday's closing bell, Aclaris Therapeutics' stock declined 1.98%, ending the trading session at $24.23.

Volume traded for the day: 2.57 million shares, which was above the 3-month average volume of 304.84 thousand shares.

Stock performance in the last month – up 8.51%

After last Friday's close, Aclaris Therapeutics' market cap was at $723.75 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.0% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors